Observation on the clinical efficacy of tiotropium combined with formoterol and salmeterol in the treatment of patients with chronic obstructive pulmonary disease
10.3969/j.issn.1009-0754.2017.03.020
- VernacularTitle:噻托溴铵联合福莫特罗与沙美特罗替卡松治疗稳定期慢性阻塞性肺疾病的疗效观察
- Author:
Yaping YUAN
1
;
Fang FANG
;
Wenchao GU
Author Information
1. 上海市浦东新区人民医院呼吸科
- Keywords:
Tiotropium;
Formoterol;
Salmeterol/fluticasone;
Chronic obstructive pulmonary disease
- From:
Journal of Navy Medicine
2017;38(3):244-247
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of tiotropium combined with formoterol and salmeterol/fluticasone in the treatment of patients with stable chronic obstructive pulmonary disease (COPD).Methods One hundred and thirty patients with moderate-to-severe COPD admitted into the hospital for treatment were enrolled for the study,and were randomized into the tiotropium plus formoterol group (or group A) and the salmeterol/fluticasone group (or group B).Following treatment for 12 weeks,scores of pulmonary functions (FEV1 和 FVC),as well as scores of CAT were compared between the 2 groups.Results Twelve weeks after treatment,the scores of FEV1,FVC and COPD of the 2 groups were all obviously increased,as compared with those before treatment,and statistical significance could be noticed,when comparisons were made between pre and post treatment (P ＜ 0.05).After treatment,the scores of FEV1 and FVC of group A were all higher than those of group B,and statistical significance could be seen,when comparisons were made between them (P ＜ 0.05).However,there was no statistical significance in the CAT scores,when comparisons were made between the 2 groups (P ＞ 0.05).Conclusion After 12 weeks of treatment,tiotropium plus formoterol therapy was obviously superior to salmeterol/fluticasone therapy in the improvement of the pulmonary functions (FEV1 and FVC) in the patients with moderate-to-severe COPD.
